A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies

dc.contributor.author	Hartl, Dominik
dc.date.accessioned	2026-01-26T12:40:44Z
dc.date.available	2026-01-26T12:40:44Z
dc.date.issued	2025
dc.identifier.issn	1359-6446
dc.identifier.uri	http://hdl.handle.net/10900/174311
dc.language.iso	en	de_DE
dc.publisher	London : Elsevier Sci Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.drudis.2025.104306	de_DE
dc.subject.ddc	610	de_DE
dc.title	A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies	de_DE
dc.type	Article	de_DE
utue.quellen.id	20250630000000_01717
utue.publikation.seiten	104306	de_DE
utue.personen.roh	Schuhmacher, Alexander
utue.personen.roh	Grinchenko, Kyrylo
utue.personen.roh	Gassmann, Oliver
utue.personen.roh	Hartl, Dominik
utue.personen.roh	Hinder, Markus
dcterms.isPartOf.ZSTitelID	Drug Discovery Today	de_DE
dcterms.isPartOf.ZS-Issue	3	de_DE
dcterms.isPartOf.ZS-Volume	30	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE